ClinicalTrials.gg
RecruitingNCT07940413Updated Nov 16, 2026

Bronchial Artery Embolization and Bronchoscopy in The Management of Hemoptysis in Cavitary Tuberculosis Lung Lesions

An interventional study of Bronchial artery embolization and Bronchial artery embolization combined with bronchoscopy in Bronchial Artery Embolization, Bronchoscopy and Hemoptysis, sponsored by Al-Azhar University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Al-Azhar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aimed to evaluate the efficacy and safety of combining Bronchial artery embolization with bronchoscopy in the management of hemoptysis in patients with cavitary pulmonary tuberculosis.

Read the detailed description

The lungs have a dual arterial supply composed of the pulmonary and bronchial arterial systems. The pulmonary arteries account for 99% of the arterial supply and are responsible for gaseous exchange.

Combining bronchoscopy with Bronchial artery embolization may improve treatment outcomes and reduce recurrence rates. Despite the increasing use of Bronchial artery embolization, limited studies have evaluated the combined role of bronchoscopy and Bronchial artery embolization specifically in patients with cavitary pulmonary tuberculosis.

02

Conditions studied

  • Bronchial Artery Embolization
  • Bronchoscopy
  • Hemoptysis
  • Cavitary Tuberculosis
  • Lung

Browse trials for

03

In context

Hemoptysis

38 studies on the registry are indexed under Hemoptysis; 7 are open to participants now.

This study's planned enrollment of 30 is below the median of 72 across 21 interventional studies indexed under Hemoptysis.

Browse Hemoptysis studies →

Lead sponsor

Al-Azhar University is the lead sponsor of 532 studies on the registry; 173 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • Confirmed pulmonary tuberculosis.
  • Presence of cavitary lung lesions on computed tomography (CT) chest.
  • Moderate or massive hemoptysis requiring intervention.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Coagulopathy not corrected before intervention .
  • Severe cardiac instability.
  • Pregnancy.
  • Pulmonary .
  • Refusal to participate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Group A

    Patients will undergo bronchial artery embolization alone.

    Procedure: Bronchial artery embolization

  • Experimental
    Group B

    Patients will undergo bronchial artery embolization combined with bronchoscopy.

    Procedure: Bronchial artery embolization combined with bronchoscopy

Interventions

  • ProcedureBronchial artery embolization

    Patients will undergo bronchial artery embolization alone.

  • ProcedureBronchial artery embolization combined with bronchoscopy

    Patients will undergo bronchial artery embolization combined with bronchoscopy.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving Successful Control of Hemoptysis

    Percentage of participants achieving complete cessation of hemoptysis without requiring an additional intervention to control bleeding will be recorded.

    Time frame: 24 hours after completion of the assigned intervention

Secondary outcomes

  1. Proportion of Participants With Recurrent Hemoptysis

    Percentage of participants experiencing a new episode of hemoptysis after initial successful bleeding control will be recorded.

    Time frame: 24 hours after completion of the assigned intervention

  2. All-Cause Mortality

    Percentage of participants who die from any cause during the specified follow-up period will be recorded.

    Time frame: 24 hours after completion of the assigned intervention

  3. Need for repeat embolization

    Percentage of participants requiring an additional bronchial artery embolization procedure because of persistent or recurrent hemoptysis will be recorded.

    Time frame: 24 hours after completion of the assigned intervention

  4. Incidence of procedure-related complications

    Incidence of procedure-related complications will be recorded.

    Time frame: 24 hours after completion of the assigned intervention

  5. Length of hospital stay

    Length of hospital stay will be recorded from the admission till discharge from the hospital

    Time frame: Till discharge from the hospital (Up to two weeks)

07

Study locations

1 of 1 sites recruiting
  • Al-Azhar University (Assiut)
    Asyut, 71511, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2026 (actual). Primary completion is estimated for Sep 2028, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940413
Responsible party
Mohamad Bahgat Abd-Elhafiz (Assistant Specialist of Chest Diseases, Faculty of Medicine, Al-Azhar University, Assiut, Egypt., Al-Azhar University) — Principal investigator
First posted
Nov 16, 2026
Start date
Sep 1, 2026
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Mohamad B Abd-Elhafiz, MBBCH
Contact
mohamedbahget1990@gmail.com
00201140466319

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion